Your browser doesn't support javascript.
loading
Therapeutic Potential of Kappa Opioid Agonists.
Beck, Tyler C; Hapstack, Matthew A; Beck, Kyle R; Dix, Thomas A.
Afiliación
  • Beck TC; Drug Discovery & Biomedical Sciences, Medical University of South Carolina, 280 Calhoun Street, QF204, Charleston, SC 29424-2303, USA. beckt@musc.edu.
  • Hapstack MA; College of Medicine, 173 Ashley Ave., Charleston, SC 29424-2303, USA. beckt@musc.edu.
  • Beck KR; College of Medicine, 173 Ashley Ave., Charleston, SC 29424-2303, USA. hapstack@musc.edu.
  • Dix TA; College of Pharmacy, The Ohio State University, 500 W 12th Ave, Columbus, OH 43210-9998, USA. beck.735@osu.edu.
Pharmaceuticals (Basel) ; 12(2)2019 Jun 20.
Article en En | MEDLINE | ID: mdl-31226764
ABSTRACT
Many original research articles have been published that describe findings and outline areas for the development of kappa-opioid agonists (KOAs) as novel drugs; however, a single review article that summarizes the broad potential for KOAs in drug development does not exist. It is well-established that KOAs demonstrate efficacy in pain attenuation; however, KOAs also have proven to be beneficial in treating a variety of novel but often overlapping conditions including cardiovascular disease, pruritus, nausea, inflammatory diseases, spinal anesthesia, stroke, hypoxic pulmonary hypertension, multiple sclerosis, addiction, and post-traumatic cartilage degeneration. This article summarizes key findings of KOAs and discusses the untapped therapeutic potential of KOAs in the treatment of many human diseases.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos